{"id":6799,"date":"2024-09-16T10:41:15","date_gmt":"2024-09-16T14:41:15","guid":{"rendered":"https:\/\/bridgebio.local\/?page_id=6799"},"modified":"2024-09-17T14:55:16","modified_gmt":"2024-09-17T18:55:16","slug":"bbp-418","status":"publish","type":"page","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/","title":{"rendered":"BBP-418"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":37,"featured_media":0,"parent":6774,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/page-affiliate.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6799","page","type-page","status-publish","hentry"],"acf":{"affiliate_color":{"color":"#479343","affiliate_body_class":"affiliate-BBP-418 limb-girdle"},"enable_exit_site_modal":true,"affiliate_hero":{"hero_header_size":"Big","background_image":{"ID":6775,"id":6775,"title":"affiliate-bg-green","filename":"affiliate-bg-green.jpg","filesize":247746,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green.jpg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/affiliate-bg-green\/","alt":"","author":"37","description":"","caption":"","name":"affiliate-bg-green","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:07:59","modified":"2024-09-16 14:07:59","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":2520,"height":1017,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-300x121.jpg","medium-width":300,"medium-height":121,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-768x310.jpg","medium_large-width":768,"medium_large-height":310,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-1024x413.jpg","large-width":1024,"large-height":413,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-1536x620.jpg","1536x1536-width":1536,"1536x1536-height":620,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-2048x827.jpg","2048x2048-width":2048,"2048x2048-height":827}},"title":"BBP\u2011418","content":"<p>BBP\u2011418 is an investigational, oral therapy that was designed to supply supraphysiological levels of the substrate used by fukutin\u2011related protein (FKRP) during glycosylation of alpha\u2011dystroglycan (\u03b1DG). If approved, BBP\u2011418 has the potential to be the first disease\u2011modifying oral therapy available for people with limb\u2011girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9).<\/p>\n","content_logo":false,"content_logo_link":"","button":"","image":{"ID":6786,"id":6786,"title":"patient_resources_hero_family_full","filename":"patient_resources_hero_family_full.webp","filesize":389828,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full.webp","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/patient_resources_hero_family_full\/","alt":"Group family photo of six people, one of whom is seated in a wheelchair and diagnosed with LGMD2I\/R9, all smiling and standing closely together","author":"37","description":"","caption":"","name":"patient_resources_hero_family_full","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:24","modified":"2024-09-16 15:11:27","menu_order":0,"mime_type":"image\/webp","type":"image","subtype":"webp","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":1988,"height":1202,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full-150x150.webp","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full-300x181.webp","medium-width":300,"medium-height":181,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full-768x464.webp","medium_large-width":768,"medium_large-height":464,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full-1024x619.webp","large-width":1024,"large-height":619,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full-1536x929.webp","1536x1536-width":1536,"1536x1536-height":929,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient_resources_hero_family_full.webp","2048x2048-width":1988,"2048x2048-height":1202}},"mobile_image":{"ID":6787,"id":6787,"title":"patient-resources-hero-family-mobile","filename":"patient-resources-hero-family-mobile.webp","filesize":80290,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile.webp","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/patient-resources-hero-family-mobile\/","alt":"Group family photo of six people, one of whom is seated in a wheelchair and diagnosed with LGMD2I\/R9, all smiling and standing closely together","author":"37","description":"","caption":"","name":"patient-resources-hero-family-mobile","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:25","modified":"2024-09-16 15:11:25","menu_order":0,"mime_type":"image\/webp","type":"image","subtype":"webp","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":932,"height":646,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile-150x150.webp","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile-300x208.webp","medium-width":300,"medium-height":208,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile-768x532.webp","medium_large-width":768,"medium_large-height":532,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile.webp","large-width":932,"large-height":646,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile.webp","1536x1536-width":932,"1536x1536-height":646,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/patient-resources-hero-family-mobile.webp","2048x2048-width":932,"2048x2048-height":646}}},"affiliate_blocks":[{"block_type":"text-block","text_block":{"content":"<h2>glycosylation substrate pro\u2011drug for LGMD2I\/R9<\/h2>\n<p>The therapeutic hypothesis behind BBP\u2011418 is that supplying supraphysiological levels of substrate to FKRP can harness the residual activity of the enzyme to glycosylate alpha\u2011dystroglycan (\u03b1DG). Although FKRP does not function at full capacity in people with limb\u2011girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9), some of the enzyme\u2019s function is retained. Harnessing this residual function may help stabilize muscle cells during contraction, with the goal of slowing or stopping further muscle damage.<sup>1<\/sup><\/p>\n","external_link":"","center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"image-row","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":[{"image_header":"Proposed mechanism of action of BBP\u2011418 in LGMD2I\/R9 muscle tissue","image":{"ID":6795,"id":6795,"title":"BBP\u2011418-chart-2-Desktop","filename":"BBP\u2011418-chart-2-Desktop.svg","filesize":183393,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp%e2%80%91418-chart-2-desktop\/","alt":"The image shows the process of orally administered BBP-418 (synthesized, pharmaceutical-grade ribitol) contributing to the glycosylation of \u03b1DG through the interaction with ISPD and mutant FKRP enzymes. The diagram highlights how the potential partial restoration of \u03b1DG glycosylation could help stabilize the muscle cell membrane and restore its ability to repair damage. On the right side, a sequence demonstrates how muscle lengthening contraction leads to a small membrane tear, which is then stabilized and repaired due to the action of BBP-418, restoring muscle membrane integrity.","author":"37","description":"","caption":"","name":"bbp%e2%80%91418-chart-2-desktop","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:37","modified":"2024-09-16 15:10:21","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Desktop.svg","2048x2048-width":1,"2048x2048-height":1}},"mobile_image":{"ID":6776,"id":6776,"title":"BBP\u2011418-chart-2-Mobile","filename":"BBP\u2011418-chart-2-Mobile.svg","filesize":200603,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp%e2%80%91418-chart-2-mobile\/","alt":"The image shows the process of orally administered BBP-418 (synthesized, pharmaceutical-grade ribitol) contributing to the glycosylation of \u03b1DG through the interaction with ISPD and mutant FKRP enzymes. The diagram highlights how the potential partial restoration of \u03b1DG glycosylation could help stabilize the muscle cell membrane and restore its ability to repair damage. On the right side, a sequence demonstrates how muscle lengthening contraction leads to a small membrane tear, which is then stabilized and repaired due to the action of BBP-418, restoring muscle membrane integrity.","author":"37","description":"","caption":"","name":"bbp%e2%80%91418-chart-2-mobile","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:17","modified":"2024-09-16 15:13:22","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/BBP\u2011418-chart-2-Mobile.svg","2048x2048-width":1,"2048x2048-height":1}}}],"image_footnotes":"<p><strong>\u03b1DG<\/strong>, alpha\u2011dystroglycan; <strong>CDP<\/strong>, cytidine diphosphate; <strong>CTP<\/strong>, cytidine triphosphate; <strong>FKRP<\/strong>, fukutin\u2011related protein; <strong>ISPD<\/strong>, isoprenoid synthase domain\u2011containing protein; <strong>LGMD2I\/R9<\/strong>, limb\u2011girdle muscular dystrophy type 2I\/R9; <strong>P<\/strong>, phosphate; <strong>R<\/strong>, ribitol.<\/p>\n"},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"text-block","text_block":{"content":"<p>The results of BBP\u2011418 Phase 1 and Phase 2 studies supported the initiation of the FORTIFY Phase 3 registrational study in LGMD2I\/R9. BBP\u2011418 has received rare pediatric disease designation, fast track designation, and orphan drug designation for the treatment of LGMD2I\/R9 from the United States Food and Drug Administration and orphan drug designation for LGMD from the European Medicines Agency.<\/p>\n","external_link":"","center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"text-block","text_block":{"content":"<h2>clinical program\u200b<\/h2>\n<hr \/>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05775848\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"alignnone size-full wp-image-6772\" src=\"\/wp-content\/uploads\/2024\/09\/fortify-logo.svg\" alt=\"fortify logo \" \/><\/a><\/p>\n<p>FORTIFY (NCT05775848) is a global, randomized, double\u2011blind, placebo\u2011controlled Phase 3 registrational study evaluating the safety and efficacy of BBP\u2011418 in people with LGMD2I\/R9. The trial is active in the US, Europe, and Australia. More information about the trial can be found on <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05775848\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov<\/a>.<\/p>\n","external_link":"","center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"references","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"<p><strong>References<\/strong><\/p>\n<ol>\n<li>Cataldi MP, Lu P, Blaeser A, Lu QL. Ribitol restores functionally glycosylated \u03b1\u2011dystroglycan and improves muscle function in dystrophic FKRP\u2011mutant mice. <em>Nat Commun<\/em> 2018;9(1):3448.<\/li>\n<\/ol>\n","cta_button":null},{"block_type":"articles","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":true,"articles":false,"manual_button_content":true,"button_link":{"title":"SEE MORE","url":"\/news\/","target":""},"display_single_column":true},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"publications","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":true,"publications":false,"manual_buttone_content":false,"button_link":"","display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null}],"footer_reference_number":"MAT-US\u2014401"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9<\/title>\n<meta name=\"description\" content=\"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9\" \/>\n<meta property=\"og:description\" content=\"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T18:55:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/\",\"url\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/\",\"name\":\"BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-09-16T14:41:15+00:00\",\"dateModified\":\"2024-09-17T18:55:16+00:00\",\"description\":\"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"what is LGMD2I\/R9?\",\"item\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BBP-418\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9","description":"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/","og_locale":"en_US","og_type":"article","og_title":"BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9","og_description":"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.","og_url":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/","og_site_name":"BridgeBio","article_modified_time":"2024-09-17T18:55:16+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BridgeBioPharma","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/","url":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/","name":"BBP-418 | Glycosylation Substrate Pro-Drug For LGMD2I\/R9","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-09-16T14:41:15+00:00","dateModified":"2024-09-17T18:55:16+00:00","description":"If approved, BBP-418 has the potential to be the first disease-modifying oral therapy available for people with LGMD2I\/R9. Learn more today.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/bbp-418\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"what is LGMD2I\/R9?","item":"https:\/\/bridgebio.com\/lgmd2i-r9\/"},{"@type":"ListItem","position":3,"name":"BBP-418"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6799"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6799"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6799\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6774"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}